‘High proliferative cribriform prostate cancer’ defines a patient subgroup with an inferior prognosis
Histopathology · 2023
DOI: 10.1111/his.15012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von Mari Bogaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helse Sør-Øst RHF, Kreftforeningen, Norges Forskningsråd.
Abstract (Originalsprache)
Aims
A cribriform pattern, reactive stroma (RS), PTEN, Ki67 and ERG are promising prognostic biomarkers in primary prostate cancer (PCa). We aim to determine the relative contribution of these factors and the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA‐S) score in predicting PCa prognosis. Methods and results We included 475 patients who underwent radical prostatectomy (2010–12, median follow‐up = 8.7 years). Cribriform pattern was identified in 57% of patients, PTEN loss in 55%, ERG expression in 51%, RS in 39% and high Ki67 in 9%. In patients with multiple samples from the same malignant focus and either PTEN loss or high Ki67, intrafocal heterogeneity for PTEN and Ki67 expression was detected in 55% and 89%, respectively. In patients with samples from two or more foci, interfocal heterogeneity was detected in 46% for PTEN and 6% for Ki67. A cribriform pattern and Ki67 were independent predictors of biochemical recurrence (BCR) and clinical recurrence (CR), whereas ERG expression was an independent predictor of CR. Besides CAPRA‐S, a cribriform pattern provided the highest relative proportion of explained variation for predicting BCR (11%), and Ki67 provided the highest relative proportion of explained variation for CR (21%). In patients with a cribriform pattern, high Ki67 was associated with a higher risk of BCR [hazard ratio (HR) = 2.83, P < 0.001] and CR (HR = 4.35, P < 0.001).
Conclusions
High Ki67 in patients with a cribriform pattern identifies a patient subgroup with particularly poor prognosis, which we termed ‘high proliferative cribriform prostate cancer’. These results support reporting a cribriform pattern in pathology reports, and advocate implementing Ki67.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
- Department of Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
- Department of Urology, Akershus University Hospital, Lørenskog, Norway.
ORCID-Profile: Mari Bogaard
Förderung
- Helse Sør-Øst RHF
- Kreftforeningen
- Norges Forskningsråd
Zitieren
APA
Bogaard, M., Skotheim, R. I., Maltau, A. V., Kidd, S. G., Lothe, R. A., Axcrona, K., & Axcrona, U. (2023). ‘High proliferative cribriform prostate cancer’ defines a patient subgroup with an inferior prognosis. Histopathology. https://doi.org/10.1111/his.15012
Vancouver
Bogaard M, Skotheim RI, Maltau AV, Kidd SG, Lothe RA, Axcrona K, et al. ‘High proliferative cribriform prostate cancer’ defines a patient subgroup with an inferior prognosis. Histopathology. 2023. doi:10.1111/his.15012
BibTeX
@article{Bogaard2023,
author = {Bogaard, Mari and Skotheim, Rolf I and Maltau, Aase V and Kidd, Susanne G and Lothe, Ragnhild A and Axcrona, Karol and Axcrona, Ulrika},
title = {‘High proliferative cribriform prostate cancer’ defines a patient subgroup with an inferior prognosis},
journal = {Histopathology},
year = {2023},
doi = {10.1111/his.15012}
}
EUVIMED